Detalles de la búsqueda
1.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Am J Hematol
; 95(4): 362-371, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31868245
2.
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Blood Adv
; 5(3): 823-828, 2021 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33560394
3.
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Clin Cancer Res
; 25(19): 5832-5842, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31300450
4.
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
J Clin Oncol
; 35(5): 490-497, 2017 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28029303
5.
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
J Clin Oncol
; 35(35): 3898-3905, 2017 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28976790
Resultados
1 -
5
de 5
1
Próxima >
>>